Animal studies of prophylaxis
- PMID: 9845495
- DOI: 10.1016/s0002-9343(97)00059-4
Animal studies of prophylaxis
Abstract
Antiviral and immune-based intervention strategies have been evaluated in vivo in animal models based on infections with lentiviruses and other retroviruses to explore their effect on preventing or limiting de novo virus infection. Variables that can be experimentally manipulated to address specific questions relevant to postexposure prophylaxis (PEP) include timing of initiation of treatment, duration of treatment, dosing regimen, virus strain, and virus inoculum. Prevention of the establishment of infection by PEP has been documented under defined experimental conditions. However, in the event that early intervention is not effective in preventing infection, evidence supporting control of viral replication and disease progression mediated by early intervention has also been reported. Thus, PEP may have a significant impact in preventing or altering viral replication in vivo and disease course.
Similar articles
-
Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1167-73. doi: 10.1089/088922201316912772. AIDS Res Hum Retroviruses. 2001. PMID: 11522186
-
Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.J Infect Dis. 2003 Aug 1;188(3):424-7. doi: 10.1086/376531. Epub 2003 Jul 10. J Infect Dis. 2003. PMID: 12870124
-
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).Antivir Chem Chemother. 2003 Jan;14(1):49-59. doi: 10.1177/095632020301400105. Antivir Chem Chemother. 2003. PMID: 12790516
-
Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.Intervirology. 1997;40(5-6):295-303. doi: 10.1159/000150563. Intervirology. 1997. PMID: 9675635 Review.
-
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.Clin Pharmacokinet. 2004;43(9):595-612. doi: 10.2165/00003088-200443090-00003. Clin Pharmacokinet. 2004. PMID: 15217303 Review.
Cited by
-
Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV.Drug Saf. 2001;24(8):587-97. doi: 10.2165/00002018-200124080-00003. Drug Saf. 2001. PMID: 11480491 Review.
-
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).J Virol. 2000 Oct;74(20):9771-5. doi: 10.1128/jvi.74.20.9771-9775.2000. J Virol. 2000. PMID: 11000253 Free PMC article.
-
Risk and management of blood-borne infections in health care workers.Clin Microbiol Rev. 2000 Jul;13(3):385-407. doi: 10.1128/CMR.13.3.385. Clin Microbiol Rev. 2000. PMID: 10885983 Free PMC article. Review.
-
Noninvasive ventilation for patients near the end of life: what do we know and what do we need to know?Crit Care Med. 2008 Mar;36(3):1003-4. doi: 10.1097/CCM.0B013E318165FD78. Crit Care Med. 2008. PMID: 18431302 Free PMC article. No abstract available.
-
Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.Cancer Stud Ther. 2020 Jul;5(2):https://researchopenworld.com/towards-covid-19-prophylaxis-an-aids-preclinical-research-perspective/. Epub 2020 Jul 19. Cancer Stud Ther. 2020. PMID: 32905553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
